Integra LifeSciences (NASDAQ:IART) Issues Q1 2025 Earnings Guidance

Integra LifeSciences (NASDAQ:IART - Get Free Report) updated its first quarter 2025 earnings guidance on Tuesday. The company provided earnings per share guidance of 0.400-0.450 for the period, compared to the consensus earnings per share estimate of 0.560. The company issued revenue guidance of $375.0 million-$385.0 million, compared to the consensus revenue estimate of $411.7 million. Integra LifeSciences also updated its FY 2025 guidance to 2.410-2.510 EPS.

Integra LifeSciences Trading Up 0.7 %

NASDAQ:IART traded up $0.15 during mid-day trading on Friday, hitting $23.21. 698,610 shares of the stock traded hands, compared to its average volume of 618,446. The company has a quick ratio of 0.73, a current ratio of 1.20 and a debt-to-equity ratio of 0.79. The stock has a market capitalization of $1.79 billion, a price-to-earnings ratio of -257.86, a PEG ratio of 0.73 and a beta of 1.17. Integra LifeSciences has a 52 week low of $16.81 and a 52 week high of $40.92. The firm's 50 day moving average is $23.77 and its two-hundred day moving average is $21.85.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last issued its quarterly earnings results on Tuesday, February 25th. The life sciences company reported $0.97 earnings per share for the quarter, topping the consensus estimate of $0.85 by $0.12. Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. The firm had revenue of $442.65 million for the quarter, compared to the consensus estimate of $445.15 million. During the same period in the prior year, the business posted $0.89 earnings per share. The company's revenue for the quarter was up 11.5% on a year-over-year basis. On average, equities research analysts predict that Integra LifeSciences will post 2.45 earnings per share for the current year.

Wall Street Analysts Forecast Growth

IART has been the topic of a number of research analyst reports. Morgan Stanley started coverage on shares of Integra LifeSciences in a report on Monday, December 2nd. They issued an "underweight" rating and a $20.00 price target on the stock. Citigroup upped their target price on shares of Integra LifeSciences from $16.00 to $22.00 and gave the stock a "sell" rating in a research note on Tuesday, November 5th. Three equities research analysts have rated the stock with a sell rating, five have issued a hold rating and one has given a buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $23.00.

Insider Transactions at Integra LifeSciences

In related news, EVP Michael J. Mcbreen sold 1,700 shares of the business's stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $24.16, for a total value of $41,072.00. Following the completion of the transaction, the executive vice president now owns 56,182 shares of the company's stock, valued at $1,357,357.12. The trade was a 2.94 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 3.10% of the company's stock.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.